Comparing Automated TFF Systems, Competitive Strategies, Product Pipelines and Growth Opportunities

There is no single automated tangential flow filtration (TFF) system that is the best choice for every GMP bioprocessing application.

The right platform depends on batch volume, molecule type, membrane format, process scale, automation requirements, single-use strategy, data integrity requirements, and future commercial capacity.

However, for companies looking specifically for highly automated, scalable TFF designed for modern biologics manufacturing, Repligen’s KrosFlo RS series is among the strongest systems to evaluate. The platform is designed for automated ultrafiltration and diafiltration (UF/DF), supports batch volumes from 35 mL to 2,000 L, and is positioned for GMP manufacturing, including applications such as mRNA and gene therapy.

The broader KrosFlo portfolio also provides a development-to-manufacturing platform, ranging from the KR2i system for 2 mL to 15 L processing through pilot-scale and GMP manufacturing systems.

But the real question for biopharma manufacturers is bigger:

Which TFF platform provides the best combination of automation, GMP readiness, scalability, process control, technology flexibility, and long-term commercial value?

That question is becoming increasingly important as biologics, biosimilars, cell and gene therapies, and RNA-based medicines expand manufacturing complexity.

Connect with us for complete guidance or further enquiry at [email protected]

Why Automated TFF Is Becoming a Critical GMP Manufacturing Technology

Tangential flow filtration is used across bioprocessing for operations including:

• Concentration
• Buffer exchange
• Diafiltration
• Desalting
• Purification support
• Product recovery
• Viral vector processing
• mRNA and RNA processing
• Monoclonal antibody manufacturing
• Vaccine manufacturing

Traditional TFF operations can require substantial operator involvement to monitor pressure, flow, transmembrane pressure (TMP), concentration, and process endpoints.

Automation changes the value proposition.

An advanced automated system can potentially provide:

More consistent process control + reduced manual intervention + improved reproducibility + electronic data capture + easier scale-up + stronger process monitoring.

For GMP manufacturers, this matters because process consistency and data integrity are commercial as well as technical priorities.

FDA’s current biologics regulatory infrastructure reflects the scale and diversity of products requiring controlled manufacturing. The FDA Purple Book contains information on FDA-licensed biological products regulated by both CDER and CBER, including biosimilars, interchangeable biologics, cellular and gene therapies, hematologic products, allergenic products, and vaccines. The database continued to publish monthly updates through August 2026.

FDA also recorded 18 biosimilar approvals for 10 reference products in 2025, highlighting continued biologics competition and the resulting need for efficient and scalable manufacturing infrastructure.

Best Automated TFF Systems for GMP Bioprocessing: The Competitive Landscape

1. Repligen KrosFlo RS: Strong Choice for Automated GMP UF/DF

Repligen’s KrosFlo RS series is designed specifically for advanced automated TFF applications and GMP manufacturing.

According to Repligen, the KrosFlo RS platform supports fully automated UF/DF for batch volumes ranging from 35 mL to 2,000 L. The systems are single-use and designed with capabilities including automation, low hold-up volumes, and scalability for modern modalities.

This makes the platform particularly relevant for companies working across:

• mRNA
• RNA therapeutics
• Gene therapy
• Viral vectors
• Biologics
• Other advanced modalities

Key Competitive Strengths

• Automated process operation
• Single-use workflow
• GMP-oriented design
• Broad processing range
• Scalability
• Support for newer modalities

For a company planning to move from process development into GMP manufacturing, the ability to standardize platforms across scales can be strategically valuable.

Best Fit

Biotech companies, CDMOs and biopharma manufacturers seeking automated TFF with a pathway toward larger-scale GMP manufacturing.

2. Repligen KrosFlo KR2i: Strong for Development and Scale-Down Work

The KrosFlo KR2i is designed for research and process development rather than large-scale commercial manufacturing.

It supports UF/DF batch volumes from 2 mL to 15 L and includes 13 automated process control modes. The system can work with hollow-fiber filters and flat-sheet cassettes.

Its Automatic Back Pressure Valve technology is designed to automate TMP control and reduce hands-on operator involvement during TFF processing. Repligen also states that its KMPi software platform offers an optional 21 CFR Part 11 package for validated GMP processes.

Best Fit

Process development laboratories that need automation and want greater continuity with a broader TFF platform family.

The Most Important Buyer Criteria for GMP TFF Systems

The word “automated” should not be the only selection criterion.

A serious GMP procurement decision should evaluate at least eight areas.

1. GMP and Data Integrity Readiness

Ask:

• Is the automation architecture suitable for validated operations?
• Is electronic data capture available?
• Is audit trail functionality available?
• Does the software support user access controls?
• Is 21 CFR Part 11 functionality available where required?
• What validation documentation does the supplier provide?

A system can be highly automated but still create substantial validation work for the manufacturer.

2. Scalability

The ideal platform should support a rational development pathway.

A manufacturer should ask:

Can process parameters developed at small scale be transferred to pilot and commercial manufacturing without rebuilding the process strategy from the beginning?

Repligen positions its KrosFlo family as a standardized platform spanning development through larger-scale processing, with shared automation and process-control concepts across systems.

For buyers, scalability can reduce both technical and commercial risk.

3. Process Automation and Control

Evaluate automation for:

• TMP
• Feed flow
• Permeate flow
• Pressure
• Diafiltration
• Concentration
• Endpoint control
• Alarms
• Data logging
• Recipe management

Repligen’s KR2i, for example, includes automated process modes and automatic back-pressure control intended to support more consistent TMP management.

The strongest future platforms will increasingly move toward:

Automation → real-time monitoring → predictive process control.

4. Molecule and Modality Compatibility

Not every TFF process behaves the same way.

A platform selected for monoclonal antibodies may not automatically be the optimal choice for:

• LNPs
• mRNA
• Viral vectors
• Exosomes
• Cell therapies
• Highly shear-sensitive biologics

The growth of advanced modalities means buyers should evaluate performance based on their specific process.

Repligen specifically identifies the KrosFlo portfolio for applications ranging from conventional biologics to newer modalities, including mRNA and gene therapy.

5. Single-Use Strategy

Single-use manufacturing can reduce cleaning requirements and improve flexibility, but buyers need to assess:

• Consumable availability
• Supplier capacity
• Supply-chain redundancy
• Extractables and leachables requirements
• Waste generation
• Cost per batch

The strongest purchasing strategy is not simply asking, “Is this system single-use?”

Instead ask:

Can our organization build a reliable, commercially sustainable supply chain around this platform?

6. Total Cost of Ownership

The equipment purchase price is only one component.

Companies should evaluate:

System cost + consumables + filters + flow paths + validation + installation + training + maintenance + spare parts + software + service + operator time.

Automation can have a higher initial cost but potentially create value through improved process consistency and reduced manual intervention.

The ROI calculation should therefore be linked to actual manufacturing metrics.

7. Supplier Support

For GMP manufacturing, supplier support can directly affect timelines.

Evaluate:

• Application support
• Process development expertise
• Field service availability
• Validation documentation
• Training
• Response times
• Global service footprint
• Spare-parts availability

For a global CDMO, supplier service capabilities may be nearly as important as the system itself.

8. Future Product Roadmap

Before selecting a system, ask the supplier:

What comes next?

A platform should be evaluated against its future capabilities, including:

• AI-assisted process analytics
• PAT integration
• Real-time concentration measurement
• Advanced sensors
• Digital twins
• Remote monitoring
• Automated recipe optimization
• Predictive maintenance

A platform with a strong roadmap can reduce the risk of technology obsolescence.

Competitive Analysis: Where Is the Automated TFF Market Heading?

The automated TFF competitive landscape is evolving across several technology layers.

Hardware Competition

Companies compete on:

• Pump performance
• Pressure control
• Sensor integration
• Hold-up volume
• Flow range
• Portability
• Scalability

Consumables Competition

Competitive differentiation also comes from:

• Hollow-fiber filters
• Flat-sheet cassettes
• Membranes
• Single-use flow paths
• Connectors

Automation Competition

The next generation of competition includes:

• Automated TMP control
• Recipe-driven processing
• Closed-loop control
• Automated endpoint detection
• Reduced operator intervention

Analytics Competition

The emerging opportunity is real-time process intelligence.

Repligen’s portfolio includes Real-time Process Management technologies focused on process control and concentration analytics for TFF operations.

The future competitive advantage could increasingly depend on which company provides the best combination of:

Filtration hardware + automation + sensors + software + process analytics.

GTM Strategy: How Should Automated TFF Companies Win More Customers?

The strongest go-to-market strategy should not target “biopharma companies” as one customer group.

Instead, segment the market.

Segment 1: Emerging Biotech Companies

Primary challenge:

Limited internal manufacturing infrastructure.

Value proposition:

Faster process development + easier scale-up + application support + flexible automation.

Key GTM channels:

• Scientific conferences
• Application webinars
• Technical content
• KOL partnerships
• Process-development case studies

Segment 2: CDMOs

Primary challenge:

Multiple customers, multiple modalities and variable batch requirements.

Value proposition:

Flexible platform + rapid changeover + broad process range + scalable automation.

For CDMOs, versatility can be more valuable than optimization for a single molecule.

Segment 3: Large Biopharma Manufacturers

Primary challenge:

Reliability, validation, global supply, productivity and lifecycle management.

Value proposition:

GMP readiness + data integrity + process consistency + global support + long-term roadmap.

Enterprise sales should focus on total manufacturing value rather than equipment specifications alone.

Launch Strategy for a New Automated TFF Platform

A product launch should begin with market intelligence.

Phase 1: Pre-Launch Intelligence

Analyze:

• Existing installed platforms
• Competitor product gaps
• Customer complaints
• Patent activity
• Emerging modalities
• Regulatory trends
• Pricing models
• Consumable purchasing patterns

The goal is to identify a specific unmet need.

Phase 2: Clinical and Technical Positioning

For bioprocessing equipment, the strongest message is not:

“Our system is faster.”

Instead, build evidence around:

• Reduced operator intervention
• Reproducibility
• Product recovery
• Process control
• Scalability
• Lower hold-up volume
• Data integrity

Technical data should become the foundation of commercial messaging.

Phase 3: Launch Through Application Leadership

Launch campaigns should focus on applications.

Examples:

• Automated TFF for mRNA
• Automated UF/DF for viral vectors
• TFF for LNP processing
• TFF scale-up strategies
• Reducing fouling through automated TMP control

Application-specific content captures more qualified technical leads than generic equipment promotion.

Phase 4: Build the Conversion Engine

High-intent lead-generation assets should include:

• Automated TFF comparison guides
• Vendor selection checklists
• GMP readiness checklists
• Scale-up calculators
• Technical webinars
• Case studies
• Competitor comparison pages
• Request-for-demo campaigns

This helps convert research-stage visitors into qualified commercial opportunities.

Patent Competition: Why IP Intelligence Matters in Automated TFF

Patent competition in TFF extends beyond filtration membranes.

Companies should monitor patents involving:

• Automatic TMP control
• Back-pressure valves
• Filtration process control
• Sensor technologies
• Real-time concentration monitoring
• Automated UF/DF
• Single-use assemblies
• Closed-loop control
• AI and predictive analytics

Repligen describes its Automatic Back Pressure Valve as proprietary technology for automated TMP control within compatible KrosFlo systems.

However, competitive patent strategy should not be measured simply by counting patents.

A useful patent intelligence program should investigate:

Who is filing → what technologies are being protected → where filings are increasing → which patents are approaching expiration → where white-space opportunities exist.

For equipment manufacturers, this can identify:

• Freedom-to-operate risks
• Licensing opportunities
• Acquisition targets
• R&D white spaces
• Emerging competitors

FDA’s Purple Book also provides a useful reminder that biologics competition itself includes significant exclusivity and competitive dynamics, with information on licensed biologics, biosimilars, interchangeability and applicable exclusivity included in the FDA database.

Product Pipeline: What Should Automated TFF Companies Build Next?

The next-generation TFF pipeline is likely to focus on five major areas.

1. Real-Time Analytics

The industry is moving toward greater visibility into process performance during production.

Future systems will increasingly integrate:

• Concentration monitoring
• Advanced pressure sensing
• Inline analytics
• Process alarms
• Automated endpoint determination

2. Closed-Loop Process Control

The next evolution after basic automation is autonomous response.

Instead of simply recording a pressure change, a system could adjust process parameters based on predefined control strategies.

3. AI-Enabled Process Optimization

AI could potentially support:

• Process anomaly detection
• Fouling prediction
• Parameter optimization
• Batch-to-batch comparison
• Predictive maintenance

For GMP applications, adoption will depend on validation, explainability, data integrity and regulatory expectations.

4. Advanced Modality Processing

Equipment pipelines will increasingly target:

• mRNA
• RNA therapeutics
• LNPs
• Viral vectors
• Gene therapies
• Cell therapies

These modalities create different process challenges and could require more specialized automation.

5. Greater Digital Integration

The strongest future platforms may connect TFF systems with:

MES + LIMS + PAT + historian systems + electronic batch records + enterprise analytics.

That could transform TFF from an isolated unit operation into a connected manufacturing data source.

How Towards Healthcare Can Help Automated TFF Companies Generate More Leads

For a bioprocessing company, knowing the current competitors is not enough.

The critical question is:

Where is the next commercial opportunity, and how can we reach it before competitors?

Towards Healthcare can help equipment manufacturers, filtration suppliers, CDMOs and investors convert market intelligence into actionable growth strategies.

Competitive Intelligence

Benchmark companies across:

• Product portfolios
• Automation features
• Scale range
• GMP capabilities
• Applications
• Pricing strategies
• Geographic reach
• Partnerships
• Product launches
• Technology differentiation

GTM Intelligence

Identify:

• Highest-growth customer segments
• Priority geographies
• Emerging modalities
• Buyer pain points
• Distribution opportunities
• Partnership strategies
• High-intent search opportunities

This can help companies develop a more precise GTM strategy rather than relying on broad bioprocessing campaigns.

Patent and IP Intelligence

Towards Healthcare can support analysis of:

• Competitor patent portfolios
• Technology clusters
• Filing trends
• Automation innovations
• Sensor technologies
• White-space opportunities

This intelligence can support R&D, partnerships, licensing and M&A decisions.

Product Pipeline Tracking

Track competitor activity across:

• Product launches
• New system capabilities
• Automation updates
• Sensor technologies
• AI integration
• Strategic partnerships
• Acquisitions
• Manufacturing expansion

This allows companies to identify competitive shifts earlier.

Launch Strategy

A structured product launch can be built around:

Market opportunity → customer segmentation → competitor mapping → unmet need → product positioning → pricing → technical evidence → channel strategy → demand generation → lead conversion.

How This WordPress Content Can Generate High-Intent Leads

This topic attracts buyers who are already researching a major equipment decision.

High-intent SEO keywords include:

• Best automated TFF system
• Automated tangential flow filtration system
• GMP TFF system
• TFF system for bioprocessing
• Automated UF/DF system
• TFF system for mRNA manufacturing
• TFF system for viral vector manufacturing
• Repligen KrosFlo competitors
• GMP filtration equipment
• Single-use TFF system

A strong content strategy can create a conversion funnel:

Top of Funnel

What is tangential flow filtration in bioprocessing?

Middle of Funnel

Automated TFF vs manual TFF: What is the difference?

Bottom of Funnel

Best automated TFF systems for GMP manufacturing

High-Conversion Pages

Repligen KrosFlo alternatives

Automated TFF vendor comparison

GMP TFF system selection checklist

These pages can attract decision-makers including:

• VP of Manufacturing
• Process Development Directors
• CMC Leaders
• MSAT Teams
• CDMO Executives
• Bioprocess Engineers
• Procurement Leaders